Compare Vanguard Value Index Fund ETF (VTV) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Value Index Fund ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Vanguard Value Index Fund ETF trades at $220.48 (market cap $262.40B), while State Street SPDR S&P Biotech ETF trades at $154.35 (market cap $10.11B). The key difference: Vanguard Value Index Fund ETF is far larger — about 26× State Street SPDR S&P Biotech ETF's market cap, and State Street SPDR S&P Biotech ETF is more actively traded (12,903,266 versus 3,293,281). Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Value Index Fund ETF for 142 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| VTV | XBI | |
|---|---|---|
Market Cap | $262.40B | $10.11B |
Volume | 3,293,281 | 12,903,266 |
52-Week High | $227.51 | $169.55 |
52-Week Low | $182.86 | $104.99 |
Typical Hold Time | 142 Days | 37 Days |
Sector | — | Broad Market / Factor |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VTV trades at $219.97, up 0.81% with a bearish technical signal from moving averages. The ETF shows neutral oscillator readings but faces selling pressure from institutional indicators. Recent news highlights value stock outperformance in 2026, with VTV beating growth counterparts by significant margins. The fund offers a 2.3% dividend yield and low 0.03% expense ratio, attracting income-focused investors amid market rotation from growth to value strategies.
VTV presents a compelling value proposition with strong 2026 performance and institutional accumulation. However, technical weakness and long-term underperformance versus broad market indices pose risks. The ETF's low-cost structure and dividend yield support defensive positioning, but investors should weigh recent momentum against historical tracking error concerns.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
